Clinical Pharmacology & Biopharmaceutics
Open Access

Abstract

Cancer is one of the leading causes of death in USA and many pathways have been searched to deliver anticancer pharmaceuticals selectively to the tumor tissues. Nevertheless, most of available chemotherapy medications, the first line of cancer treatment modalities, are suffering from lack of targeting capabilities that leads to life threatening side effect or lowest efficacy. The importance of low-density lipoprotein (LDL) will be highlight andits implications in the field of drug delivery to cancer cells aregoing to be explored. LDL is naturally occurring bio-nanoparticles (BNP) with sizing of 25 nm. These BNPs particularlyship cholesterol to cells expressing the LDL receptors. Numerous tumors overexpress LDL receptor, to provide cholesterol for supportingthe high rate of membrane synthesis. LDL BNPs are biocompatible and biodegradable, selectively bind hydrophobic and amphiphilic drugs, are taken up by a receptor-mediated mechanism Drugs can be loaded onto LDL BNPs by surface loading, core loading, and apoprotein interaction. Therefore, LDL may be used as a drug carrier for treatment of cancer. The presentation will emphasize on the concept of drug targeting and rational for the development of targeted drug delivery systems based on lipoprotein pathway. It also will cover research reports of targeted drug delivery systems and their development basedon lipoproteins pathways. Cancer chemotherapy will be used as an example of special area of need for selective and targeted drug delivery.

Biography